SLC5A2 and hydrops fetalis: In recent years, there has been growing interest in HF due to the development of new therapies, including glucose-lowering medications, such as sodium-glucose cotransporter 2 inhibitors (SGLT2), which have demonstrated significant cardioprotective effects, leading to notable improvements in HF symptoms, reduced hospitalizations rates, and decreased mortality [11].